Concurrent therapy with other Investigational Products.
Treatment with any investigational products within 14 days before the first dose of protocol-indicated treatment
Treatment with any investigational products within 28 days prior to study registration
Treatment with any investigational products within 2 weeks before administration of the first dose of the study drugs.
Treatment with any investigational products within 30 days before randomization.
Treatment with any investigational products within 14 days before the first dose of study drug
Treatment with any investigational products within 4 weeks before the first dose of study drug.
Treatment with any investigational products within 14 days before the first dose of any study drug
Previous treatment with venetoclax and/or current participation in any other research study with investigational products.
Concurrent therapy with other investigational products
Treatment with any investigational products within 14 days before the first dose of any study drug
Treatment with any investigational products within 14 days before the first dose of study drug
Treatment with any investigational products within 3 weeks before the first dose of study drug
Treatment with any investigational products within 3 weeks before the first dose of study drug
Previous treatment with any substrate of CYP2B6 enzyme < 14 days prior to initiation of investigational products
Treatment with any investigational products within 4 weeks before the first dose of any study drug
Treatment with any investigational products within 28 days prior to study registration
Treatment with other investigational products within the last 2 months prior to entry into this study
Treatment with any anti leukemic/anti MDS therapies (eg, lenalidomide, cytarabine, anthracyclines, purine analogs) or with any investigational products within 14 days before the first dose of any study drug.
Not be allergic to tomatoes or tomato products
Treatment with any investigational products within 14 days before the first dose of study drug and systemic anticancer therapy within 28 days before the first dose of study drug.
Treatment with any investigational products within 60 days before the first dose of the study drug regimen.
Received radiation therapy =< 14 days prior to initiation of investigational products
Treatment with any investigational products within 4 weeks before the first dose of any study drug
Treatment with any investigational products within 30 days before the first dose of study drug
Treatment with any investigational products within 60 days before the first dose of the study drug regimen
Treatment with any anticancer therapy or any investigational products within 3 weeks before the first dose of study drug.
Treatment with any systemic antineoplastic therapy or investigational products within 21 days before the first dose of study treatment.
Treatment with any investigational products 21 days prior to treatment
Treatment with any investigational products
Exposure to more than 4 investigational medicinal products within 12 months prior to the first dose of study treatment
Investigational products or therapy other than ASP8273
Therapy with any investigational products within 21 days before the first dose of study drug
Abstention from meat and other animal products
Not be allergic to tomato or tomato products
Allergic to fish products
Received other investigational products or therapy in the 60 days prior to study drug administration.
Other investigational agent(s) within 21 days prior starting to study treatment.
Use of any investigational agent within 28 days prior to randomization.
Received another investigational agent within 30 days of enrollment
Prior participant in another protocol using an investigational agent within 5 half-lives of the investigational agent
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent for any indication within 30 days prior to first treatment.
Use of investigational agent within 28 days prior to randomization
Participants is taking another investigational agent
Received an investigational agent within 30 days prior to starting study treatment
The patient has received treatment with an investigational systemic anticancer agent within 28 days prior to C1D1.
Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required
Have taken an investigational agent within 30 days of visit 1
Use of any standard chemotherapy or other investigational agent(s) within 1 week of study enrollment
Received an investigational agent within 30 days prior to enrollment
Patients receiving investigational agent within 30 days of enrollment. However, the principal investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of alpha-1-antitrypsin.
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent within 30 days prior to enrollment
Patient is currently using, or planning to use another investigational agent
Use of an investigational agent within 4 weeks of enrollment (day 1)
Use of other investigational agent for prostate cancer
Received an investigational agent within 30 days prior to enrollment
Patients who participated in any therapeutic clinical study with an investigational agent within the last 30 days
Cytotoxic therapy or investigational agent use within 28 days
Treatment with a prior investigational agent within 30 days of first dose of investigational medication
Exposure to any therapeutic agent (investigational or conventional) within 7 days of date of randomization or to any agent for which 5 half lives have not elapsed
Receipt of any investigational agent or study treatment within 30 days prior to C1D1
Treatment with other investigational agent(s) within 30 days of planned lymphodepletion
Concurrent use of investigational therapeutic agent
Investigational agent within 30 days of enrollment without approval from the sponsor- principal investigator (PI)
Concurrent use of investigational therapeutic agent
At least 7 days after the last dose of a biologic agent.
Exposure to any investigational agent within 30 days of date of randomization.
The use of any investigational agent in the month before enrollment into the study
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent within 30 days prior to enrollment
Received any investigational agent for any indication within 30 days prior to first treatment.
Investigational agent: >= 28 days must have elapsed from treatment with a different investigational agent
Patients who have received any investigational treatment agent within the last 28 days.
Received an investigational agent within 30 days prior to enrollment
Patients who have received another investigational agent within the previous 3 months
Use of any investigational agent within 30 days of the first radiation dose
Use of investigational agent within last 14 days
Received any investigational agent within the 14 days before the start of ALT-803
Use of an investigational agent within 4 weeks of enrollment
Treatment with any other investigational agent within 28 days prior to enrolment.
Use of any investigational agent within the last 28 days. For classes of investigational agents that are not known to have prolonged toxicities the wash-out time may be decreased to 14 days after agreement with the Medical Monitor.
Subjects who have received an investigational agent within 30 days OR within 5 half-lives of the investigational agent (whichever is shorter) prior to the possible enrollment date on this study
Patient who has received investigation agent within 30 days prior to enrollment
Received an investigational agent within 30 days prior to enrollment
Patients who have received any investigational agent within 30 days prior to day 1
Subjects who received any investigational agent ?28 days of study drug initiation.
Subjects who received an investigational agent <14 days prior to their first day of study drug administration.
The patient has received treatment with another investigational agent within 14 days of study entry.
? 28 days elapsed from the administration of any investigational agent
Use of any investigational agent within the 4 weeks preceding enrollment
Received an investigational agent within 4 weeks prior to enrollment
Previously received an investigational antineoplastic agent for NSCLC.
Use of any investigational agent within 28 days of randomization.
Any investigational agent within the previous 30 days.
Patients who have received any investigational agent, chemotherapy, interferon-alfa, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1
Exposure to any investigational agent, systemic chemotherapy, or therapeutic radiation within 21 days of enrollment (Part 1) or randomization (Part 2).
Previously received treatment with RGX-104 or another investigational agent that is a known LXR agonist.
Use of an investigational agent or an investigational device within 28 days before administration of first dose of NKTR-214.
Concurrent use of investigational therapeutic agent
Patients must have received their last dose of any other investigational agent greater than 28 days prior to enrollment (with exception of fluorothymidine F-18 [FLT])\r\n* Patients must have received their last dose of any other biologic agent greater than 7 days prior to enrollment
Use of investigational agent within 28 days prior to Randomization
Subjects who received an investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-120 should not occur before a period ?5 half-lives of the investigational agent has elapsed.
Use of an investigational agent within 2 weeks of enrollment (day 1 visit)
Received an investigational agent within 4 weeks prior to enrollment
Subjects who are receiving any other investigational agents or who have received an investigational agent within 28 days prior to enrollment (does not apply to participation in survival follow up), or who have previous exposure to vandetanib
Subjects who received a small molecule investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-221 should not occur before a period ?5 half-lives of the investigational agent has elapsed.
Patients who have received any investigational agent within 4 weeks of enrollment
Receipt of any other investigational agent within the 28 days prior to Day 1.
Treatment with an investigational agent ? 30 days prior to randomization
Concurrent therapy with any other investigational agent
Patients who have received any other investigational agent in a 28-day period prior to enrollment in this study
Received an investigational agent within 30 days prior to enrollment
Received anticancer agent(s) or an investigational agent within 21 days prior to C1D1, or radiotherapy within 28 days prior Cycle 1 Day 1
Use of an investigational agent, including an investigational anti-cancer agent, within 14 days prior to the first dose of study drug
Treatment with investigational agent within 30 days prior to enrollment
Treatment with a an investigational agent within 30 days prior to the first dose of dasatinib/ATRA or planning to receive an investigational agent during the study
Patients who have received any investigational agent, chemotherapy, interferon-?, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to first dose
An investigational agent within the past 30 days
Current use of an investigational agent
Participation in an investigational research study using an investigational agent within 30 days of screening
Use of an investigational therapeutic agent with 4 weeks of enrollment
Treatment with an investigational agent within 30 days prior to the first dose of SNX?5422 or planning to receive an investigational agent during the study.
Use of any investigational agent within 28 days prior to Baseline.
Received an investigational agent within 30 days prior to enrollment
Received an investigational agent for another disease within 30 days prior to enrollment
Subjects who have received any other investigational drug or agent within 28 days of first dose of TH-302
Use of any other investigational agent within 21 days before day 1.
Use of any investigational agent within the last 28 days
Received an investigational agent <14 days prior to their first day of study drug administration. In addition, the first dose of AG-221 should not occur before a period ?5 half-lives of the investigational agent has elapsed
Exposure to any investigational agent within 30 days of date of randomization.
Exposure to any investigational agent within 30 days of Randomization.
Recently received an investigational agent or device
Received an investigational agent within 30 days prior to enrollment
Use of an investigational therapeutic agent within 30 days
Concurrent use of other investigational agent
Subject may not receive another investigational agent.
The patient received treatment with another investigational agent within 14 days of screening.
Must be 28 days from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:
Use of an investigational agent within the past 30 days
Use of any investigational agent within 28 days prior to start of CA-4948
Treatment with any other investigational agent within 28 days prior to randomization
Any other investigational agent within 28 days of study entry
Patient received chemotherapy, biological or investigational agent ? 28 days prior to enrollment.
Received an investigational agent for any indication within 30 days prior to first treatment
Received an investigational agent within 30 days prior to enrollment
Concurrent use of investigational therapeutic agent
Concurrent use of investigational therapeutic agent
Received an investigational agent within 30 days prior to enrollment
28 days from the administration of any investigational agent
Patient is currently receiving or has received another investigational agent within 30 days or monoamine oxidase inhibitor within 14 days prior to Lazanda administration
Received an investigational agent within 30 days prior to enrollment
Concurrent therapy with an investigational agent
Received any investigational agent =< 28 days before Treg infusions
Use of any investigational agent within 30 days of randomization
Use of investigational agent within 30 days of study entry
Has received an investigational study agent within the previous 30 days, or is currently participating in or scheduled to participate in any other clinical study with an investigational agent during the 12-week study period
Exposure to any investigational agent (defined as any agent not approved by the Food and Drug Administration [FDA]) within 30 days prior to the Screening Visit
Use of non-study investigational agent(s) =< 3 months prior to randomization
Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgery
Subjects must not receive concurrent or prior use of an immunosuppressive agent within 14 days of the first dose of investigational agent, with the following exceptions and notes:
Subjects must not have received another investigational agent within the shorter of 4 weeks or 5 half-lives before the first dose of investigational agent.
Received an investigational agent within 30 days prior to enrollment
Use of an investigational agent within 4 weeks of enrollment
Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgery
Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study
Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment\r\n* >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Patients must have received their last dose of known myelosuppressive anticancer therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea
Patients must not have received myelosuppressive therapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Myelosuppressive chemotherapy: must not have received within 4 weeks of registration onto this study (6 weeks if prior nitrosourea)
Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least 21 days prior to study registration or at least six weeks if nitrosourea; at least two weeks must have lapsed if patients received lower dose oral etoposide (50 mg/2) without experiencing evidence of myelosuppression (i.e. neutropenia or requiring transfusion with blood products)
Myelosuppressive chemotherapy: at least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea)
Myelosuppressive chemotherapy: Must not have received within 4 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea).
Myelosuppressive chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosourea
Myelosuppressive chemotherapy: Must not have received within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea).
Patients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosourea
INCLUSION CRITERIA FOR STRATUM C: Patients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosourea
Chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study enrollment in the study or at least six (6) weeks for those receiving nitrosourea
Participant has received no prior radiotherapy or chemotherapy for RMS (excluding steroids); at least 6 weeks must have passed since last dose of myelosuppressive chemotherapy or radiation therapy for conditions other than RMS; patients must have recovered from acute toxicity of any prior myelosuppressive chemotherapy or radiation therapy; prior biopsy, surgical resection and lymph node sampling is allowed
Myelosuppressive chemotherapy
Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosourea
Myelosuppressive chemotherapy, immunotherapy, or any investigational agent: ? 21 days (? 42 days if a nitrosourea) prior to screening.
Must not have received myelosuppressive chemotherapy within 21 days prior to study drug administration (42 days if prior nitrosourea).
Myelosuppressive chemotherapy: must not have received within 4 weeks of entry onto this study
Patients must not have received myelosuppressive chemotherapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Patients must not have received myelosuppressive therapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Chemotherapy: \r\n* Must not have received myelosuppressive chemotherapy within 3 weeks of the study entry (6 weeks if prior nitrosourea); prior treatment with either dasatinib or temsirolimus but not both is allowed; at least 3 weeks must have elapsed from the last dose
Patients must have recovered from the toxic effects of prior therapy to grade 1 or better; patients must be at least 3 weeks form the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy
At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
Myelosuppressive chemotherapy: must not have received within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Must not have received myelosuppressive chemotherapy and/or biologics within 3 weeks of entry onto this study (4 weeks if prior nitrosourea)
Myelosuppressive chemotherapy: Must not have received within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea).
Patient must have received last dose of known myelosuppressive chemotherapy > 21 days prior to enrollment; > 42 days if nitrosurea
Evidence of recovery from any prior chemotherapy; no myelosuppressive anticancer chemotherapy or biological therapy within 3 weeks (6 weeks if a nitrosourea or mitomycin C agent) prior to registration
Myelosuppressive chemotherapy: must not have received within 28 days of entry onto this study (42 days if prior nitrosourea drug) accompanied by hematopoietic recovery or 14 days of stopping non-myelosuppressive therapy as long as hematopoietic requirements are met
Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ?21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea).
Myelosuppressive chemotherapy: must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study (excluding hydroxyurea)\r\n* Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of CPX-351
Myelosuppressive chemotherapy: at least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)
MDS: No previous myelosuppressive therapy; for the purpose of this protocol myelosuppressive chemotherapy will be defined as chemotherapy given with the intent of inducing a complete remission (e.g., standard 7+3, high dose intermittent ARA-C [HIDAC], or Mylotarg)
MPD: No previous myelosuppressive therapy; for the purpose of this protocol myelosuppressive chemotherapy will be defined as chemotherapy given with the intent of inducing a complete remission (e.g., standard 7+3, HIDAC, or Mylotarg)
Atypical CML: No previous myelosuppressive therapy; for the purpose of this protocol myelosuppressive chemotherapy will be defined as chemotherapy given with the intent of inducing a complete remission (e.g., standard 7+3, HIDAC, or Mylotarg)
Patients must have received their last dose of known myelosuppressive anticancer therapy greater than 28 days prior to study enrollment or > 42 days if nitrosourea
Myelosuppressive chemotherapy: must not have received within 4 weeks of entry onto this study
Myelosuppressive chemotherapy: Must not have received within 3 weeks (6 weeks if prior nitrosourea)
Myelosuppressive chemotherapy:\r\n* Subjects must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks if nitrosourea
Cytotoxic chemotherapy or other chemotherapy known to be myelosuppressive: ?21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)
Myelosuppressive chemotherapy: interval >= 6 weeks and >= 4 weeks from last dose of nitrosourea and other chemotherapy drugs before study enrollment, respectively; however, interval must be >= 1 week from last dose of oral etoposide and other drugs administered at low doses (metronomic regimen) before study enrollment
Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks if nitrosourea
Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment (6 weeks if prior nitrosourea)
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must have received their last dose of known myelosuppressive anticancer therapy or immunotherapy at least 21 days prior to enrollment (42 days if prior nitrosourea)
Patients must not have received myelosuppressive therapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)
Myelosuppressive chemotherapy: Last dose was given at least 14 days before the start date for protocol therapy.
Chemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks prior to study entry (6 weeks if prior nitrosourea)
Planned non-myelosuppressive chemotherapy regimen
Patient must not have had myelosuppressive chemotherapy =< 3 weeks prior to entry onto this study (or 6 weeks if prior nitrosourea)
Chemotherapy: ?14 days from any myelosuppressive chemotherapy and abs neutrophil ct ?1000/mm3 , 42 days if prior nitrosurea
Stem cell infusions (with or without total body irradiation [TBI]):\r\n* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion, and no evidence of graft-versus-host disease (GVHD)\r\n* Autologous stem cell infusion including boost infusion: >= 42 days
Participants must be at least 100 days after the transplantation or a donor lymphocyte infusion
Donor lymphocyte infusion within 100 days prior to enrollment
Planned use of prophylactic donor lymphocyte infusion (DLI) therapy.
Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible
Patients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusion
Patients receiving a donor lymphocyte infusion within 4 weeks of planned T cell infusion
Subjects who developed aGVHD after unplanned donor lymphocyte infusion.
TREATMENT WITH SJCAR19: Prior to planned SJCAR19 infusion, patients with a history of prior allogeneic HCT must be at least 3 months from HCT, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
Subjects must be at least 100 days from prior stem cell transplant (autologous or allogeneic) or donor lymphocyte infusion (DLI)
Donor lymphocyte infusion administered to treat relapse or loss of donor chimerism
Prior donor lymphocyte infusions (DLIs) are not necessary
Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration
Patients who have had donor lymphocyte infusion (DLI) within 8 weeks prior to registration
Donor lymphocyte infusion within 100 days prior to enrollment
Subjects must not have received a donor lymphocyte infusion (DLI) within 8 weeks prior to the first dose of study medication
Has received donor lymphocyte infusion (DLI) product within 6 weeks of CAR T cell infusion
High dose therapy with autologous hematopoietic cell infusion (At least 60 days from last infusion prior to first dose of tazemetostat)
ELIGIBILITY CRITERIA FOR T-CELL PRODUCT INFUSION: Absolute lymphocyte count < 500/ul or patient has received lymphodepleting chemotherapy administered at least 24 hours prior to T cell infusion
Patients who have received donor lymphocyte infusion (DLI) within 28 days of Viralym-A infusion.
Patients who have received donor lymphocyte infusion (DLI) within 28 days
Patients who have received donor lymphocyte infusion (DLI) within 28 days
No change in dosing of immunosuppressive agents in the 2 weeks preceding the naive T-cell depleted donor lymphocyte infusion
A commitment not to electively taper for a minimum of 60 days, the immunosuppressive medications ongoing at time of naive T-cell depleted donor lymphocyte infusion
Patients developing SR aGvHD after donor lymphocyte infusion (DLI) or after withdrawal of immunosuppression are eligible
Donor lymphocyte infusion within 8 weeks prior to treatment start if post-transplant
Logistical requirements:\r\n* Space available in infusion room\r\n* Outpatient infusion pump available if continuous infusion required\r\n* Case discussed with infusion room nursing staff
Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease (GVHD)
Autologous stem cell infusion including boost infusion: ?42 days
Unplanned donor lymphocyte infusion (DLI) for residual or relapsed malignancy or mixed chimerism. DLI as part of the planned HCT protocol is allowed.
Less than 2 months following bone marrow or peripheral blood stem cell transplantation or treatment with donor lymphocyte infusion (DLI).
Donor lymphocyte infusion (DLI) is considered a reinduction attempt.
At least 4 weeks (from first dose) elapsed from donor lymphocyte infusion (DLI) without conditioning.
Patients with acute GVHD developing after a donor lymphocyte infusion.
Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
The patient has, or accepts to have, an acceptable infusion device for infusion of melflufen
Donor lymphocyte infusion (DLI) within 28 days prior to enrollment
Donor lymphocyte infusion within 100 days prior to enrollment
Donor lymphocyte infusion within 12 wks prior to starting dose of AMG 592.
Donor lymphocyte infusions (DLI) within 2 months prior to leukapheresis
Stem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: ?42 days
Patients may have had prior treatment for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), including lenalidomide; patient may have had prior autologous or allogeneic transplant (family member, unrelated donor, or cord blood) if there is at least 90 days between transplant and study entry; patients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry; patients on immunosuppression are also eligible
DONOR: Must consent to granulocyte-colony stimulating factor (G-CSF) (filgrastim) administration and leukapheresis for both PBSC allograft and subsequent donor lymphocyte infusion (DLI)
Subjects who received an unplanned (not part of the original transplant therapy plan) donor lymphocyte infusion.
Allogeneic cellular therapy: Donor lymphocyte infusions (DLI) are prohibited within 4 weeks prior to leukapheresis
Participant whose GvHD developed after donor lymphocyte infusion
The patient will need to be available for evaluation within 72 hours of symptoms of GVHD, occurring within 60 days of the planned donor lymphocyte infusion
No chemotherapy, RT, donor lymphocyte infusion (DLI) or biologic therapy for lymphoma at least 4 weeks prior to scheduled treatment
Patients who have received donor lymphocyte infusion (DLI) within 28 days of Viralym-C infusion.
Received donor lymphocyte infusion (DLI) within 28 days
Treatment with Epstein-Barr virus cytotoxic T lymphocytes, chimeric antigen receptor (CAR)-T cells directed against B cells, or unselected donor lymphocyte infusion (DLI) within 8 weeks of Cycle 1 Day 1
Patients may also have had donor lymphocyte infusion if there is at least 60 days between donor lymphocyte infusion and study entry
Anticipated planned donor lymphocyte infusion in the first 3 months post-SCT
Patients may have received a prior allogeneic hematopoietic stem cell transplant (alloHSCT) for any indication and from any donor; patients developing cGvHD after donor lymphocyte infusion (DLI) are also eligible
Received a donor lymphocyte infusion (DLI) or hematopoietic cell transplantation (HCT) within 3 months of enrollment
Planned use of prophylactic donor lymphocyte infusion (DLI) therapy
Donor lymphocyte infusion within 100 days prior
Patients who have received donor lymphocyte infusion (DLI) within 28 days
Patients whose GVHD developed after donor lymphocyte infusion (DLI)
Donor lymphocyte infusion in the preceding 100 days
Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
FOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
No donor lymphocyte infusion (DLI) prior to day 100, and no plans for a DLI in the upcoming 30 days
Patients may have received no more than one donor lymphocyte infusion (DLI), DLI must have been administered > 6 weeks prior to enrollment on study, and no plans for a DLI in the upcoming 30 days
Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration
At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion (DLI) without conditioning.
Other anticancer or experimental therapy; no other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-vascular endothelial growth factor [VEGF]/fetal liver kinase 1 [Flk-1] monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment
Use of any other experimental medication(s) within 14 days prior to start of the study treatment.
Use of any other experimental drug or therapy within 28 days of starting treatment with abatacept
Recent (within 4 weeks of registration), current, or planned participation in another experimental drug study
Use of any other experimental drug or therapy within 21 days prior to first dose
Current, recent (within 4 weeks of the first dose of this study), or planned participation in an experimental drug study with an experimental agent
Treatment with an experimental therapy within the last 28 days
Participant has used experimental therapy for acute GVHD within 4 weeks of randomization. If unsure of the definition of \experimental\, discussion with one of the protocol chairs is recommended.
Concurrent treatment with other experimental treatments for NSCLC while on the study
Prior treatment with radium-223 dichloride or any experimental radiopharmaceutical.
Experimental therapies within 4 weeks before first ZW25 dosing
Involved in other experimental protocols (except with permission of the other study PI)
Use of experimental drug within 4 weeks of treatment
The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drugs is < 5 times the half-life of the previously administered agent(s).
Other concurrent experimental therapies
Use of any other experimental drug or therapy within 28 days of baseline
Patients receiving other experimental immunotherapy
Receiving another experimental drug within 4 weeks of initiation of conditioning (day -6) unless approved by the PI
Use of any other experimental drug or therapy within 28 days of baseline.
Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
Anticancer treatment within designated period before enrollment including\r\n* Minor surgical procedure (such as biliary stenting) within 14 days\r\n* Major surgical procedure or radiation treatment within 28 days\r\n* Chemotherapy or experimental drug treatment with published half-life known to be 72 hours within 14 days\r\n* Experimental drug treatment with unpublished or half-life greater than 72 hours within 28 days\r\n* Radiotherapy for measurable lesions delivered in a normal organ-sparing technique within 21 days (except for palliative radiotherapy)
Concomitant therapy with any other experimental drug
Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Patients receiving any other anticancer or experimental drug therapy
Current, recent (within 4 weeks of the administration of this study agent), or planned participation in another experimental therapeutic drug study
Patients must not be scheduled to receive another experimental drug while on this study.
Patients must not be scheduled to receive another experimental drug while on this study
Patients who have been treated with any investigational drug within 28 days prior to the first dose of study medication, or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Prior experimental therapy within 30 days of enrollment
Current, recent (within 3 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Prior experimental therapy within 4 weeks of planned start of this trial
Receiving other experimental therapy
Patients must not be scheduled to receive another experimental drug while on this study
Prior use of experimental agents for prostate cancer
Participants must be more than 14 days removed from most recent minor surgical procedure (such as biliary stenting), 28 days from most recent major surgical procedure, 14 days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be 72 hours or less and 28 days removed from last experimental drug treatment with unpublished or half-life greater than 72 hours
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Prior experimental therapy within 30 days of planned start of this trial
Use of any other experimental drug or therapy within 21 days of baseline
Patients who have received experimental agents within 4 weeks of study entry
Use of any other experimental drug or therapy =< 28 days prior to registration on this study; NOTE: Patients on low dose prednisone (=< 10 mg) for treatment of conditions other than CLL are eligible
Patients who have previously taken mebendazole as part of any experimental anti-cancer protocol, and have failed this therapy
Patients who are currently receiving any other experimental agent, must have stopped other experimental agents at least 21 days prior to 1st study dose
Experimental therapy within 4 weeks prior to first dose of study drug treatment on Study Day 1 of Period A
Involved in other experimental protocols (except with permission of the other study PI)
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in any other experimental drug study
Use of any other experimental drug or therapy within 14 days of baseline
Patients must not be scheduled to receive another experimental drug while on this study
Current, or recent (within 4 weeks of the first treatment of this study) cytotoxic chemotherapy (e.g. cisplatin, taxol) or experimental drug therapy, or planned participation in an experimental drug study
Patients who have taken part in an experimental drug study within 4 weeks of initiating study treatment with sonidegib
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
Patients who have taken part in an experimental drug study =< 4 weeks prior to registration
For the MF and MDS/MPN-U arms (arms 1 & 2), use of any other standard drug (except hydroxyurea, anagrelide, growth factors, Revlimid, clofarabine, etc) or experimental drug or therapy within 14 days of starting study therapy
Use of any other experimental drug or therapy within 21 days of study-related drug therapy
Patient should not be getting any other experimental therapy for aGvHD
Serology:\r\n* Seronegative for human immunodeficiency virus (HIV) antibody (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Use of any other experimental drug or therapy within 28 days of baseline
Patients receiving any other anticancer or experimental drug therapy
Patients who have had prior chemotherapy, experimental agents for prostate cancer, or patients receiving more than 8 weeks of prior hormone therapy will be excluded
Planned participation in any other experimental drug study
Use of any other experimental drug or therapy =< 28 days prior to registration
Use of any other experimental drug or therapy within 28 days of baseline.
Requirement of radiotherapy to treat brain metastases or receipt of any non-study systemic therapy for cancer or any other experimental/investigational treatment.
Patient is receiving everolimus in combination with an unapproved or experimental treatment
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent treatment with other experimental drugs or any other systemic anticancer therapy (due to unknown drug-vaccine potential interactions)
Subject is receiving or is less than 14 days since ending other experimental drug (no marketing authorization for any indication)
4 weeks from prior experimental drug
No other experimental therapy is permitted while on study
Receiving another experimental drug within 4 weeks before initiation of conditioning (day -6)
Current, recent (within 4 weeks of the first treatment of this study), or planned participation in an experimental drug study (prevention trials are permitted if the trial is not testing a novel experimental agent)
Patient must have no plans to receive any other experimental therapy while on the protocol treatment; previous experimental therapy must have been completed at least 28 days prior to registration
Participation in a clinical trial using experimental therapy within the last 4 weeks prior to randomization
Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.
Prior AML or ALL therapy (non-experimental) within 28 days of first dose of ONO-7475 (except those permitted in the protocol)
Planned treatment with other experimental drugs or any other non-hormonal anti-cancer therapy;
Use of any other experimental drug or therapy within 28 days of baseline
Use of any other standard or experimental therapy within 14 days of starting study therapy
Prior treatment with another experimental anti-tumor vaccine is permissible
No experimental medications within 30 days of study entry
Other experimental drugs =< 4 weeks prior to registration
Seronegative for human immunodeficiency virus (HIV) antibody; the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment
Use of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose >= 4 mg/day or prednisone >= 20 mg/day), within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; hydroxyurea is permitted up to 24 hours before the first dose of study drug in patients with rapidly-proliferating disease
Other concurrent experimental or investigational drugs
Current, recent (within 4 weeks of the administration of this study agent), or planned participation in an experimental drug study
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment
No experimental intravesical therapy within 6 weeks of study entry
For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
COHORT A: Concomitant therapy with any other experimental drug
COHORT B: Concomitant therapy with any other experimental drug
Patient is currently participating in other experimental studies that could affect the primary endpoint (e.g. experimental chemotherapy regimen).
Patients receiving or participating on any other experimental agents/clinical trials are not eligible for participation
Experimental medications within the last 4 weeks prior to day 1
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy
Use of any other experimental drug or therapy within 28 days of baseline
Concomitant use of other anticancer (except for corticosteroids) or experimental agents
Have received antimyeloma treatment, radiotherapy, or any experimental drug or therapy within 2 weeks before the first infusion
Receipt of an experimental vaccine within 2 months or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months, or has received any previous gene therapy using an integrating vector
Concomitant therapy with any other experimental drug
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
Use of any other experimental drug or therapy within 28 days of baseline
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Use of any other experimental drug or therapy within 28 days of baseline.
Current, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug study
Subjects on any other systemic therapy for cancer, including any other experimental treatment
Any experimental therapy ? 28 days prior to randomization
Patient has used any other anti-cancer drug or therapy, including experimental, within 30 days of initiation of lenalidomide treatment (radiation therapy is allowed within 30 days)
Use of any other experimental drug or therapy within 28 days of baseline
Patients receiving any other anticancer or experimental drug therapy
Use of any other experimental drug or therapy other than carfilzomib and pomalidomide within 28 days of treatment start on this protocol
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Use of any other experimental anti-cancer drug or therapy within 28 days of initiation of the study drug
Use of experimental drugs ? 30 days prior to screening
Any experimental imaging agent directed at amyloid within 2 weeks
Antileukemia or experimental treatment within 4 weeks of study drug (other than hydroxyurea or 6-mercaptopurine)
Use of any experimental immunotherapy.
Prior therapy with abiraterone, orteronel, ketoconazole, or any other Cytochrome P450 (CYP) 17 lyase inhibitor; enzalutamide or other experimental androgen receptor antagonist; or experimental immunotherapy agent.
Therapeutic or experimental monoclonal antibodies in last 60 days prior registration.
Pregnant patients may not receive this experimental therapy
Another experimental anti-amyloid therapy other than NEOD001 within 2 years
Receiving other experimental therapy
Use of any experimental immunotherapy.
Current, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug study
4 weeks from prior experimental drug
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g. donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy
Have received experimental therapy within 2 weeks of enrollment
Experimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1
Use of any other experimental drug or therapy within 14 days of baseline
Use of any other standard or experimental therapy within 14 days of starting study therapy
Currently receiving any other experimental therapy or has received any other experimental therapy within the 4 weeks prior to enrollment
Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study
Treatment with an experimental drug within 28 days of first dose
Use of any other experimental drug or therapy within 21 days of baseline
Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of entry
Patients who have taken part in an experimental drug study within 4 weeks of initiating treatment with LDE225
At least 30 days must have elapsed since any prior experimental therapy
Concurrent therapy with other anti-neoplastic or experimental agents
Received previous treatment with any c-MET experimental therapeutic.
Use of any other experimental drug or therapy within 28 days of baseline
Use of any other experimental drug or therapy within 28 days prior to randomization
Seronegative for human immunodeficiency virus (HIV) antibody; Note: The experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment
Experimental therapy within 4 weeks prior to first dose of study drug
Be willing to be randomized to experimental conditions
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication)
Use of any other experimental drug or therapy within 28 days of baseline
Concurrent participation in other experimental studies that could affect the primary endpoint
Involved in other experimental protocols except with permission of other PI
Patients who are participating in another experimental protocol during the study period (last intake of investigational drug within 6 months prior to first study drug injection)
Experimental immunotherapies: 3 months
Involved in other experimental protocols (except with permission of the other study PI)
Involved in other experimental protocols (except with permission of the other study PI)
Subjects may not be receiving any experimental therapies
Patients on any experimental anti-EGFR targeted therapies
Donors receiving experimental therapy or investigational agents.
Experimental therapy within 4 weeks prior to first dose of study drug treatment in Cycle 1
At least a 6 month interval since completion of prior radiation
Low grade NHL: with < 6 month duration of CR between courses of conventional therapy
Variceal bleeding within 1 month prior to study registration
Predisposing characteristics for acute pancreatitis in the last month prior to randomization.
Patient with irregular cycles (more than once a month)
Participant who is breastfeeding or planning to breastfeed for a month post last dose of study agent
Inability to start the protocol treatment within 1 month after study enrollment
Administration of chemotherapy within the last 1 month
History of active immunotherapy in the previous month.
No prior radiation therapy or chemotherapy within 1 month of study enrollment
Active or recent (prior 6 month) invasive fungal infection without interdisciplinary (ID) consult and approval
Subject had surgery (excluding line insertions) within 1 month of the first dose of study drug or has lingering wound complications.
Rx with an investigational drug w/in 1 month of infusion, other than for treatment of their underlying disease
Clinically relevant infection of any kind within the month preceding enrollment (example, active hepatitis C, pneumonia)
Brain MRI within one month prior to enrollment
Low grade NHLwith < 6 month duration of CR between courses of conventional therapy
Patients who have had influenza, hepatitis, or other vaccines within a month prior to initiation of study drugs
Corticosteroids will be allowed at enrollment and during the first month of treatment with T-DM1 after SRS, up to a dose of no more than 10 mg of dexamethasone daily or equivalent; patients that need to continue corticosteroids after the initial month will be allowed to continue in the protocol treatment if no further increase in dose is necessary; patients that need increase in dose of corticosteroid after initial month will be taken off protocol treatment
Chemotherapy (current, within the last month, or anticipated in the next 7 months)
Radiation therapy in the month prior to enroll
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol
The subject has a prior history of unrelated neoplastic disease, and has received systemic therapy for the secondary malignancy within the twelve (12) month period preceding the screening evaluation
Disease staging approximately within one month of treatment
Radiation therapy in the month prior to enrollment
Illicit drug use within the last month
Is in an immunosuppressed state (e.g. HIV +, use of chronic steroids [> 1 month])
Progressive lymphocytes with an increase of >= 50% over a 2-month period or an anticipated doubling time of less than 6 months OR
PART 2: Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
Patients with myelodysplastic syndromes refractory (primary or acquired resistance) to hypomethylating agents; at least 4 1-month cycles of prior decitabine or SGI-110 (guadecitabine) OR 6 1-month cycles of 5-azacytidine (intravenous [IV], subcutaneous, or oral) is required unless the patient has progressive disease prior to completing the required number of cycles
Patients who have had flu, hepatitis, or other vaccines within a month prior to initiation of study drugs
Concurrent uncontrolled medical illness that is deemed by the investigator to have potential to interfere with the delivery of chemotherapy for a six month time period
Patients who have previously taken omega-3 fatty acid within 1 month prior to study enrollment
Patients who have an uncontrolled infection (presumed or documented) with progression after appropriate therapy for greater than one month
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol; however, cell harvesting by leukapheresis may be performed before one month from prior therapy if the study investigators consider that it will not have a detrimental impact on the generation of the two cell therapies in this protocol
Use of oral glucocorticoids within 1 month of screening
Active pneumonia within 1 month prior to starting treatment
Active or recent (prior 6 month) invasive fungal infection without infectious diseases (ID) consult and approval
Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
Received immunosuppression post hematopoietic transplant within 1 month of study entry
Clinically relevant infection of any kind within the month preceding enrollment (eg, active hepatitis C, pneumonia)
Clinically relevant infection of any kind within the preceding month of enrollment
recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery
Radiation therapy in the month prior to enroll
Active or recent (prior 6 month) invasive fungal infection unless cleared by innovation and development (ID) consult
Anticipated lifespan greater than 3 month
Signed informed consent for the focal laser ablation (FLA) treatment through the 12 month follow up visit
Anti-angiogenic therapy within the last month
Age < 18 years and > 1 month (< 1 month upon approval by Sponsor)
night sweats for > 1 month without evidence of infection
Patients of fertile age who refuse contraception for a twelve month period post-transplant
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol
Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol; however, cell harvesting by leukapheresis may be performed before one month from prior therapy if the study investigators consider that it will not have a detrimental impact on the generate of the two cell therapies in this protocol
Disease staging approximately within one month of treatment
The subject must be willing to apply the medications twice daily for 1 month
History of myocardial infraction (MI) within 6 month prior to starting study treatment
Anticipated lifespan greater than 6 month.
Patients may not be receiving or have received any other investigational agents during/or within 1 month prior to treatment with oregovomab or nelfinavir
Having smoked at least one cigarette within 1 month of cancer diagnosis
Patient taking varenicline or bupropion within one month of study enrollment
Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 1 month after the last dose of sorafenib
Prior daily use of tadalafil or other long-acting phosphodiesterase-5 (PDE5) inhibitors for one month or greater
Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
Cancer vaccines and convection-enhanced therapies: interval >= 1 month before study enrollment
Subjects who received any investigational medication, prior local therapy for pancreas cancer , or any significant change in treatment within 1 month prior to screening
Use of systemic glucocorticoids such as prednisone or Decadron in the last month
Participants may have received prior TKI therapy, however must be on a stable dose of their current TKI for at least one month prior to enrollment
If spinal metastases is within previously irradiated field, there must be a 6 month interval between prior radiation course and study registration
Low-grade NHL with < 6 month duration of CR between courses of conventional therapy
Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit:
Chemotherapy or investigational antineoplastic drug within 1 month of planned initiation of vaccine therapy
Receipt of treatment known to potentially affect the course of AA within last month
Received thrombolytic agents w/in the previous month
No seizures, focal weakness of any extremity (by neurologic exam), or stroke symptoms in the past month
Current (within last month) use of chemotherapy for breast or other malignancy
Recent (within last month) or current intensive manual lymphatic drainage (MLD) and/or short stretch bandage use
If patients have received radiation therapy, there must be a one-month washout period
Patients having received radiation therapy in the month prior to enrollment
More than one previous episode of CDAD in the 3-month period prior to randomization.
Chest X-ray within 1 month of registration
Patients in this study may not use vaccines for the treatment of cancer or prevention of disease unless indicated as a component of the protocol regimen (including those for common medical conditions) for up to one month pre and post dosing with ipilimumab
Traumatic catheterization within 1 month
Glaucoma diagnosed within one month prior to study Day 1.
Treatment with highly active antiretroviral therapy (HAART) for at least 1 month
Patients that start chemotherapy or radiotherapy during the study time (1 month post diagnostic bronchoscopy), will be excluded from the study
Radiation therapy in the month prior to enroll
No recent history (=< 90 days) of substance abuse (outside of tobacco) defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) as:\r\n* If male, drinking > 14 alcoholic beverages per week for past 1 month\r\n* If female, drinking > 7 alcoholic beverages per week for past 1 month\r\n* Use of cocaine, heroin, club drugs (i.e., 3,4-methylenedioxymethamphetamine (MDMA)/ecstasy), methamphetamine, or hallucinogens (e.g., lysergic acid diethylamide [LSD]) at any time during the past 1 month\r\n* Use of marijuana on a weekly basis for the past 1 month
Within one month (+/- 1 month) of starting chemotherapy or within two weeks (+/- 2 weeks) of starting radiation therapy (may be prior to or after starting treatment)
PATIENT EXCLUSION: Life expectancy of < 1 month
Have outpatient visits at least once a month
Use of an investigational drug within 1 month prior to dosing
Major surgery/surgical therapy for any cause within 1 month prior to pasireotide administration; patients should have recovered and have a good clinical condition before entering the study
Not currently regularly practicing yoga (defined as at least once a month)
Chronic treatment with any inhaled steroid for > 1 month in past three months
Treatment with montelukast or zafirukast for > 1 month in past three months
Treatment with systemic steroids for > 1 month in past three months
Patients who will be receiving surgery or adjuvant chemotherapy within 1 month following radiation treatment
Female breast cancer survivor who is over 1 month and less than 24 months beyond the completion of primary therapy (surgery, radiation, and chemotherapy).
Participants must be willing and able to travel to CUMC for data collection and optional blood draws at two baseline visits, 6-month and 12-month visit; if needed and depending on staff availability, optional blood draws can be completed at a participants home by a certified phlebotomist from our research team
Acute coronary event within the past month
Chronic glucocorticoid or acute glucocorticoid or other synthetic steroid intake within the last month
Surgery or hospitalization within the last month
Surgical treatment in the previous month
ALS PATIENTS: Already on a stable dose of riluzole for at least one month
Severe anemia (hemoglobin [Hb] < 7g/L) if documented in the last month and not corrected prior to study enrollment
Patients must be willing to adhere to the PNP intervention and the entire 6-month study
Patients who have lost >= 5% of their usual body weight over the preceding 1 month
Received filgrastim (GCSF) treatment within one month of enrollment
Oncologists who treat at least 2 advanced cancer patients per month at a study participating hospital
History of using any of the following medications, regardless of dose, for at least 1 month, within 3 months of enrollment: anabolic agents, glucocorticoids (does not include inhaled glucocorticoids), growth hormone, parathyroid hormone (PTH)
Severe anemia (hemoglobin [Hb] < 7 g/L) if documented in the last month and not corrected prior to study enrollment; extra blood work will not be drawn unless the patient already has the lab abnormalities documented and need to be corrected
Life expectancy < 1 month or current hospice care
No planned surgery anticipated in the 3-month intervention period
At least 1 month from any major surgery to start of intervention, including colostomy reversal (Port-A-Cath removal excluded)
Narcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollment
Recent steroid treatment within the last month
Presence of hot flashes for >=1 month prior to study entry
Patient is willing to delay prostate biopsy for a 3-month finasteride treatment
Patient is willing to take finasteride 5 mg orally daily for 3-month treatment period
Patient must be above the age of 1 month as of the start date of study treatment.
Reports conducting at least 20 new initial screenings per month
Smokers who are receiving other tobacco treatment services or have used cessation medications (NRT, bupropion, varenicline) within the past month
Prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit
A cardiovascular event in the past month
Have been non-daily smokers for at least the previous year (< or = 27 days/month);
Low grade NHL  with < 6 month duration of CR between courses of conventional therapy
Provided a secondary phone or email contact to ensure one month follow-up survey completion
Suffering from a terminal illness with less than 12 month life expectancy
Terminal illness with less than 12 month life expectancy
Willing to undergo a history and physical at baseline and 12 months and be contacted periodically by the trial coordinator during the 12 month study period
STUDY I: >= 1 month of e-cigarette use
History of DHA supplementation > 200 mg/day in the month preceding study entry
A patient who has not received systemic or loco-regional treatment of the tumor within the last month.
Intravenous (IV) contrast exposure in the past 1 month
Less than 1 month since any prior prostate biopsy (to decrease false positive from inflammation)
HEALTHY VOLUNTEER: Exposure to ultrasound contrast agents (UCAs) in the 1 month prior to study initiation
The patient must agree at the time of study entry to undergo clinically indicated biopsy(ies) or 24-month period of follow-up, as needed, to resolve the etiology of their IPN(s) or lung mass(es)
Women who will receive or have already received a breast MRI within one month of the CESM
Have undergone chemotherapy or radiation therapy within the previous one month
Patients with a blood creatinine level > 2.0 mg/dl within a month of this procedure
Diabetic patients with a blood creatinine level > 1.5 mg/dl within a month of this procedure
Participants unwilling to complete the protocol (24 month duration)
Use of antibiotics one (1) month prior to or during this study
Have undergone chemotherapy or radiation therapy within the previous one month
Less than 1 month since any prior prostate biopsy (to decrease false positive uptake from inflammation)
Core biopsies obtained within 1-month of MRI/MRE
Willing to use contraception during and for 1 month after completion of the study
The subject has received, or is scheduled to receive, another IMP from 1 month before to 1 month after inclusion in this study
A history of antibiotic use within one month prior to initial PSA level measurement
Current or prior systemic use of corticosteroids in the past month
Recipient of vaccines within 1 month of or during study drug treatment.
Receiving treatment for advanced lung cancer for over one month before enrollment; OR
TIPs INCLUSION: Planning on remaining in NYC for at least 1 year, (with no vacations or trips to exceed one month)
past six month use of any e-cigarette
The patient has received any investigational therapy within 4 weeks of enrollment
Use of any investigational drugs, biologics, or devices within 30 days prior or during the study treatment.
Use of other investigational drugs at the time of screening or within the last 30 days.
Any investigational agents or drugs from a previous clinical study within 28 days
Use of other investigational drugs within 28 days prior to study drug administration
Investigational Drugs: Subjects who have received another investigational drug within the last 14 days are excluded from participation.
Other investigational drugs or investigational therapy if the patient is currently taking those drugs/therapy, or if they have received the drugs/therapy within 1 month.
Treatment with any investigational compound within 30 days prior to the first dose of study drugs
Subjects taking other investigational drugs or drugs of abuse within 30 days of entry into this study.
Patients receiving other investigational immunotherapy or anti-myeloma drugs within 14 days before enrollment.
Receipt of an investigational agent within 28 days (or 56 days for an antibody-based therapy) before the first planned dose of study drugs
Within 14 days of the first dose of the study drugs: Platelets >= 75,000/L.
Patient has used any investigational drugs, biologics (vaccines, antibodies), or devices within 30 days prior to study treatment or has plans to use any of these during the course of the study
Patient is receiving other investigational drugs
Have received other investigational drugs within 30 days of enrollment.
Participated in a previous clinical trial or used any investigational drugs, biologics, or devices within 90 days prior to study treatment or plans to use any of these during the course of the study.
Received any investigational drugs within the 14 days prior to CIML NK cell infusion date
Received investigational drugs within the 14 days before 1st dose of study drug
Investigational drugs: subjects must not have received an investigational drug within 4 weeks
Patient has received other investigational drugs with 14 days before enrollment
Received any investigational drugs within the 14 days prior to the first day of transplant conditioning
Patients who have received other investigational drugs within 14 days prior to screening
Receipt of an investigational agent within 28 days (or 60 days for an antibody-based therapy) before the first planned dose of study drugs
Exposure to other investigational drugs within 4 weeks before enrollment
Patients who are receiving other investigational drugs 14 or fewer days before enrollment
Have received other investigational drugs within 14 days prior to enrollment
Treatment with any investigational compound within 30 days prior to the first dose of study drugs
Patient has received other investigational drugs with 14 days before enrollment
Use of any investigational drugs within 30 days prior to dosing
Patients who have received other investigational drugs within 28 days of Viralym-A infusion.
Patient has received other investigational drugs within 14 days before enrollment
Investigational Drugs: Subjects who have received another investigational drug within the last 14 days are excluded from participation.
Treatment with other investigational drugs within 6 months of study entry
Patient has received other investigational drugs within 4 weeks before enrollment
Received any investigational drugs within the 14 days prior to the first dose of fludarabine
Exposure to other investigational drugs within 2 weeks before enrollment
Patient has received other investigational drugs within 3 weeks before study registration
Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
Subjects who have received any investigational drugs or devices within 4 weeks before the first day of study treatment (C1D1).
Received any investigational drugs within the 14 days before 1st dose of fludarabine
Use of other investigational drugs
Have received either of the study drugs
Participants who are receiving, or have received, any other investigational drugs or devices within the 2 weeks prior to the first dose of study medications
Patients who have received hepatotoxic drugs less than 7 days prior to enrollment
Received investigational drugs within the 14 days of study registration
Use of other investigational drugs within 28 days preceding the first dose of trametinib and during the study
Concomitant use of any other investigational drugs
Concurrent treatment with other investigational drugs.
Patient has received other investigational drugs with 14 days before treatment of treatment with bortezomib + rituximab
Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
Patient has received other investigational drugs with 14 days before enrollment
Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of study drug (day -7)
Subjects who have received investigational drugs =< 4 weeks prior to registration
Patients on other investigational drugs while on study will be excluded
Receipt of an investigational agent within 28 days (or 56 days for an antibody-based therapy) before the first planned dose of study drugs
Patient has used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study.
Subject has received other investigational drugs within 14 days prior to first dose of study drug.
Other investigational drugs within 4 weeks prior to enrollment, unless cleared by the Principal Investigator
Use of other investigational drugs within 28 days preceding the first dose of vemurafenib during this study
Investigational drugs: subjects must not have received an investigational drug within 4 weeks
Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment;
Prior use of investigational drugs =< 14 days prior to registration
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment
Concomitant use of any other investigational drugs
Receipt of an investigational agent within 30 days (or 60 days for an antibody-based therapy) before the first planned dose of study drugs
Taking other investigational drugs
Concomitant use of any other investigational drugs
Concurrent use of other investigational agents and patients who have received investigational drugs =< 4 weeks prior to enrollment
Patient has received other investigational drugs within 3 weeks before study registration
Received investigational drugs within the 14 days before enrollment
Received any investigational drugs within the 14 days before 1st dose of fludarabine
Patient has received other investigational drugs within 14 days prior to enrollment
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment.
Patient has not received other investigational drugs with 14 days before enrollment
Receipt of investigational drugs within 14 days before D1 of alisertib
Use of any investigational drugs, biologics, or devices within 28 days prior to study enrollment
Subjects receiving concomitant treatment with radiotherapy or other investigational drugs
Concomitant use of any other investigational drugs
Patient has received other investigational drugs or chemotherapy within 21 days or approved anti-myeloma therapy within 14 days.
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs within 1 week before enrollment.
Patients who have received other investigational drugs within 28 days of Viralym-C infusion
Use of other investigational drugs within 28 days preceding the first dose of vemurafenib on this study.
Use of other investigational drugs
Have taken any of the following drugs within 7 days prior to Study Day 1:
Patient has received other investigational drugs with 14 days before enrollment
Patient has received other investigational drugs with 14 days before enrollment
Use of anti-cancer treatment (including investigational drugs) within 28 days
Patients receiving concurrent investigational drugs
Patient has received other investigational drugs within 14 days of treatment initiation
Investigative drugs within 21 days
Concurrent investigational drugs
Patient has received other investigational drugs within 14 days before enrollment or who have not recovered from side effects of those therapies
Any treatment with investigational drugs within 30 days before the start of the study
Have received other investigational drugs within 28 days prior to enrollment
Other investigational drugs within 4 weeks prior to enrollment, unless cleared by the principal investigator
Concurrent participation in another study involving investigational drugs or investigational medical devices
Patient has used any investigational drugs, biologics, or devices within 14 days prior to study treatment or plans to use any of these during the course of the study
Currently receiving or has received any investigational drugs within the 14 days prior to the first dose of the conditioning regimen
Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug [IND] for initial efficacy investigations)
Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug (IND) for initial efficacy investigations
Has received investigational drugs suspected to cause peripheral neuropathy; no concurrent investigational drugs may be used
Investigational drugs: must not be receiving other investigational (from other studies) drugs at time of enrollment and must not be planning to take other investigational drugs during DLT period
Other investigational drugs
Received systemic anticancer therapy or an investigational agent <2 weeks prior to Day 1 (washout from prior immune based anticancer therapy is 4 weeks). In addition, the first dose of study treatment should not occur before a period ?5 half-lives of the investigational agent has elapsed.
Receipt of systemic anticancer therapy, including investigational agents, within 5 times the agent's elimination half-life of starting study treatment
Prior anticancer systemic therapy
Receipt of any other systemic anticancer therapy with the exception of hormonal therapy for a hormonally sensitive (e.g. breast or prostate) cancer (for treatment phase)
Receipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose.
Ongoing treatment with an anticancer agent.
Research participants receiving any other anticancer or investigational drug therapy
Systemic therapy (standard or an investigational or biological anticancer agent)
Treatment with anticancer/investigational drugs, therapy ? 4 weeks prior to first dose of SC-002
Ongoing treatment with an anticancer agent not contemplated in this protocol.
Received systemic anticancer therapy within the previous 21 days
Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.).
Receipt of anticancer medications or investigational drugs within Protocol-defined time frames.
Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 28 days before the first dose of the IMP. Hormonal therapy may be administered up to 7 days prior to the first dose of the IMP.
Received prior anticancer therapy within 21 days of first dose
Patients receiving any other anticancer or investigational drug therapy
Any cytotoxic chemotherapy, investigational agents, or anticancer drugs for advanced NSCLC used for a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
Receipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:
Cytotoxic anticancer therapy (e.g., alkylating agents, anti-metabolites, purine analogues) or any other systemic anticancer therapy within 2 weeks of study entry.
Patients who received any of the following within the 14 days before initiating study treatment: major surgery, radiation therapy, and/or systemic therapy (standard or an investigational or biological anticancer agent).
Treatment with any anticancer therapy
Anticancer chemotherapy or immunotherapy during the study or within 5-halflives prior to start of study treatment. Mitomycin C, nitrosoureas or monoclonal antibodies with anticancer activity (e.g. bevacizumab or cetuximab etc.) should not be given within 6 weeks before starting to receive study treatment or within 6 weeks of pre-treatment biopsy for biomarker (p-ERK1/2) studies
Patients who received any systemic anticancer therapy within 2 weeks before randomization.
STRATUM A: Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollment
STRATUM B: Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollment
STRATUM C: Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollment
Immunotherapy and/or investigational anticancer therapy with agents including mAbs : ?4 weeks
Last dose of anticancer therapy must have been administered within 6 months of the date of randomization into this study.
Last dose of anticancer therapy (including HER2-targeted therapy) within 14 days prior to randomization.
Concomitant use of any anticancer therapy or use of any investigational agent(s).
Receiving any anticancer therapy for biliary tract cancer =< 21 days prior to registration
The subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancer, localized prostate cancer on active surveillance, or localized solid tumors deemed cured by surgery and not treated with systemic anticancer therapy and not expected to require anticancer therapy in the next 2 years i.e., while the subject may be taking study treatment
Receipt of systemic anticancer therapy, including investigational agents, within 28 days prior to study treatment (Note: If anticancer therapy was given within 28 days prior to starting study treatment, patients are not excluded if ? 5 times the elimination half-life of the drug has elapsed.)
Patients who are actively receiving any other anticancer therapy
Any prior anticancer therapy for this diagnosis
Patients who are receiving any other anticancer agents.
Receipt of anticancer chemotherapy within 4 weeks before the administration of study drug
Receipt of anticancer chemotherapy within 4 weeks before the first administration of study drug
Patients who are receiving any other anticancer therapy
Any anticancer therapy or investigational agent within prior 3 weeks.
Systemic anticancer therapy within 21 days of the first dose of study drug\r\n* All adverse events from prior systemic therapy must have either stabilized or returned to baseline
Any investigational anticancer therapy received within 28 days prior to the first dose of durvalumab and tremelimumab
Concomitant therapy with any other anticancer therapy or chronic use of systemic corticosteroids.
Completion of prior chemotherapy systemic anticancer therapy at least 2 weeks prior to study entry
Any prior anticancer therapy
No previous anticancer therapy (radiation therapy or chemotherapy) other than use of corticosteroids
No previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroids
Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatment
Receipt of a large molecule anticancer agent (e.g., antibody), including an investigational anticancer antibody, within 28 days of starting study treatment
Patient is receiving concomitant standard and/or investigational anticancer therapy; local palliative radiotherapy is permissible upon discussion with the principal investigator
Treatment for malignancy with anticancer therapy, including cytotoxic agents, hormonal agents, or immunotherapy, within 5 years of enrollment
Patients who are receiving any other anticancer or investigational drug therapy are not eligible
Receipt of anticancer medications, anticancer therapies, or investigational drugs within the defined interval before the first administration of study drug.
Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
Anticancer Agents: participants who are currently receiving other anticancer agents
Any systemic anticancer therapy within 3 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, or anticancer immunotherapies, a washout period of 6 weeks is required. For patients in Cohort 2, this does not apply to the most recently received hormone therapy.
?3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agents
Received prior systemic anticancer treatment (chemotherapy, targeted therapies including kinase inhibitors, antibodies, etc) less than 5 half-lives before the first dose of study drug or radiotherapy within 30 days; toxicity of the anticancer treatment must have recovered to grade 1 or less.
Need for other anticancer treatment
Receipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug.
Receipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or treatment with any anticancer medications or investigational drugs within the protocol-defined intervals.
Has received prior anticancer therapy including investigational agents within 4 weeks prior to randomization
Anticancer therapy within 14 days of first G1T48 dose or within 28 days for antibody-based therapy
Investigational agent, anticancer therapy, or major surgery within 14 days (2 weeks) prior to C1D1
Any non-investigational anticancer therapy within prior 2 weeks
Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies
Not currently receiving any anticancer therapy
The subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancer or localized solid tumors deemed cured by surgery and not treated with systemic anticancer therapy and not expected to require anticancer therapy in the next 2 years i.e., while the subject may be taking study treatment. However, subjects with low-risk prostate cancer, e.g.:
Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to their first day of study drug administration. (Hydroxyurea is allowed prior to enrollment and after the start of AG-120).
No other current active malignancy requiring anticancer therapy.
Receipt of anticancer medications or investigational drugs within protocol-specified intervals
Treatment with any anticancer therapy or participation in another therapeutic clinical study with investigational drugs </=14 days (</=28 days for patients in Korea) prior to first dose of FPA144
A minimum of 1 week since the last dose of prior therapy (a minimum of 4 weeks since anticancer immune therapy or bevacizumab +/- interferon).
Patients who received systemic anticancer therapy or radiotherapy <21 days prior to their first day of study drug administration
Any type of anticancer agent (including investigational) within 2 weeks before randomization.
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
Concomitant use of any other investigational or anticancer agent(s).
Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatment
Receipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment. If anticancer therapy was given within 28 days of starting study treatment, patients may be included if 5 times the elimination half-life of the drug has passed. a biologic anticancer agent (e.g., antibody), including an investigational anticancer antibody, within 28 days of starting study treatment
Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
Completion of all prior anticancer therapy before first ACP-196 dose.
Received any anticancer medication or therapy in the 21 days prior to study Day 1
Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent within the specified time frames prior to study drug administration.
Systemic treatment with anticancer therapy within 3 weeks before study drug treatment
not discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapy
The subject has received chemotherapy, immunotherapy, or any other systemic anticancer therapy, with the exception of anti-HER2 therapy (e.g., trastuzumab), within 14 days prior to the Day 1 visit.
Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatment or receipt of a biologic anticancer agent (e.g., antibody) within 28 days of starting study treatment.
Participants who have received any anticancer treatment within 3 weeks or any investigational agent within 30 days before the first dose of study drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
Receipt of anticancer therapy:
Prior anticancer or investigational drug treatment within the following windows:
Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration.
Subjects who are currently receiving any other concomitant anticancer therapy with the EXCEPTION of bisphosphonates and hormone therapy.
Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.
The patient has received treatment with an investigational systemic anticancer agent within 14 days prior to study therapy administration.
Is receiving other concomitant anticancer treatment
Patients who are receiving any other investigation agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment and/or radiation therapy is allowed with a 14 day washout period prior to registration
Subject has received chemotherapy, immunotherapy or any other systemic anticancer therapy (including sorafenib) or any other investigational drug within 14 days prior to the Day 1 visit.
Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment;
Patients receiving any concurrent anticancer therapy or investigational agents with the intention of treating esophagogastric cancer; last prior therapy must have been completed at least 2 weeks (14 days) prior to starting nintedanib
Receipt of anticancer therapy within 28 days prior to the first dose of Investigational Product
Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment
Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment
Received systemic anticancer therapy or radiation therapy within the previous 14 days
Subjects who received systemic anticancer therapy or radiotherapy <21 days prior to their first day of study drug administration.
Prior mifepristone use for anticancer therapy is not allowed
Systemic chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy intended to treat underlying malignancy, within 3 weeks before the first dose or 6 weeks for antibody therapy
Radiotherapy or systemic therapy (standard or an investigational or biologic anticancer agent) within 14 days of initiation of study drug treatment
Patients who are receiving any other anticancer therapy
Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a 2 week washout period prior to registration
Subjects may not be receiving any other standard or investigational anticancer agents, with the exception of hormonal therapy
Must have received at least one prior systemic anticancer therapy for NSCLC
Concomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies. Low-dose corticosteroids for the treatment of non cancer-related illnesses are permitted.
No expectation of further effects of prior anticancer therapy
Any type of systemic anticancer therapy (chemotherapy or experimental drugs) within 2 weeks of starting treatment on protocol
Currently receiving anticancer therapy
Anticancer chemotherapy or immunotherapy: Anticancer therapy is defined as any agent or combination of agents with clinically proven anticancer activity administered by any route with the purpose of affecting the cancer, either directly or indirectly, including palliative and therapeutic endpoints
Systemic anticancer therapy or major surgery within 28 days prior to registration. In absence of toxicity from prior systemic anticancer therapy, 5 half-lives since completion of prior systemic anticancer therapy is allowed.
Treatment with other systemic anticancer therapy within 4 weeks prior to the first dose of study medication
Other concomitant anticancer treatment
Patients who are receiving any other investigational agents for anticancer treatment within 3 weeks of starting study medication
Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)
Previously treated with 0 to 2 lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting. Hormonal therapy and bone metastases treatment (example, bisphosphonates, denosumab, etc) are not considered forms of systemic anticancer therapy.
Receipt of anticancer medications or investigational drugs within the following interval before the first administration of study drug:
Recent therapy with any active anticancer agent within 4 weeks of the 1st dose of the study drugs
Systemic anticancer therapy within 4 weeks of study entry, except for subjects with anaplastic/undifferentiated thyroid cancer who may be enrolled immediately after discontinuation of previous therapy
Received systemic anticancer therapy or radiotherapy <21 days prior to their first day of study drug administration
Has received treatment with any systemic anticancer therapy, wide-field radiation, or experimental agent within 4 weeks of receiving cyclophosphamide on Day -3, with the exception of anticancer hormonal therapy, which may not be given within 2 weeks of receiving cyclophosphamide on Day -3. All residual toxicity related to prior anticancer therapies (excluding vitiligo, endocrinopathies on stable replacement therapy, alopecia and Grade 2 fatigue) must resolve to Grade 1 severity or less or return to baseline prior to receipt of study treatment.
Receipt of anticancer therapy:
Any chemotherapy, anticancer antibodies, or other systemic anticancer therapy within 21 days of the first dose of study drug
Systemic anticancer therapy within 28 days
Has had certain other recent treatment e.g. major surgery, extended field radiation, anticancer therapy, received investigational agent, within the specified time frames prior to study drug administration
Any therapy that is potentially immunosuppressive or has anticancer activity in the 4 weeks prior to device microinjection
Anticipated ongoing concomitant anticancer therapy during the study.
Have received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drug
Currently receiving anticancer therapy or have received anticancer therapy within the past 28 days or 5 half-lives of the anticancer therapy
Anticancer chemotherapy, experimental cancer therapy, or cancer immunotherapy within 4 weeks prior to first dose study drug. Anticancer therapy is defined as any agent or combination of agents with clinically proven anti tumor activity administered by any route with the purpose of affecting the malignancy, either directly or indirectly, including palliative and therapeutic endpoints.
Receipt of other anticancer therapy within 2 - 6 weeks, depending on the treatment
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
Chemotherapy with approved or investigational anticancer therapeutics within 21 days prior to randomization.
Need for concomitant anticancer therapy (surgery, radiation therapy, chemotherapy, immunotherapy, radiofrequency ablation) or other investigational agents during the study treatment period.
Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea, low dose cytarabine and intrathecal chemotherapy
Participated in a prior anticancer investigational study =< 30 days prior to enrollment, or =< 5 half-lives of the anticancer investigational product, whichever is longer (treatment with somatostatin analogue [SSTa] while on dovitinib is allowed provided patients tumor has progressed on therapy prior to initiating dovitinib treatment)
Treatment with high-dose corticosteroids for anticancer purposes within 7 days before the first dose of TAK-659.
Toxicity from previous anticancer treatment.
Receipt of any conventional or investigational anticancer therapy within 4 weeks prior to the first dose of durvalumab and IPH2201
Participant has received anticancer therapy or any investigational therapy within a period of 21 days prior to the first dose of ABBV-085.
Patients who have declined further anticancer therapy will be excluded
Use of other anticancer therapy within 15 days before the first dose of M3541 administration and should not be within the \at risk follow-up period\ for that specific anticancer therapy. The use of any investigational agent is not allowed within 28 days before the first dose of M3541
On any new anticancer therapy (GnRH analog allowed) while on the study
Treatment with anticancer chemotherapy or biologic therapy or with an experimental anticancer agent within 28 days of the initial dose of study drug.
Systemic anticancer treatment (including investigational agents) or radiotherapy less than 2 weeks before the first dose of study treatment (<=4 weeks for large molecule agents; <=8 weeks for cell-based therapy or anti-tumor vaccine), or not recovered from the reversible effects of prior anticancer therapy.
Receipt of anticancer medications or investigational drugs within the protocol-defined intervals before the first administration of study drug.
Participants who have received any anticancer treatment within 21 days or any investigational agent within 30 days (or 5 half-lives) prior to the first dose of study drug and should have recovered from any toxicity related to previous anticancer treatment. This does not apply to the use of TSH suppressive thyroid hormone therapy.
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug
Receipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment. If anticancer therapy was given within 28 days of starting study treatment, patients may be included if 5 times the elimination half-life of the drug has passed
The subject has received another investigational agent within 21 days of the first dose of study drug
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The participant has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The participant has received another investigational agent within 14 days of the first dose of study drug
Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
mCRPC EXPANSION COHORT: The patient has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Receipt of any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Any other type of investigational agent within 4 weeks before the first dose of study treatment
RENAL COHORT: The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Any other type of investigational agent within 28 days before the first dose of study treatment
Investigational agent received within 30 days prior to the first dose of study drug
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
Having received an investigational agent within 30 days prior to the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The participant has received any other type of investigational agent within 28 days before the first dose of study treatment
Treatment with any investigational agent within 28 days before the first dose of study treatment
Having received an investigational agent with 21 days of receiving the first dose of study drug on this trial
Use of any other type of investigational agent or treatment concurrently or within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any other type of investigational agent within 28 days before the first dose of study treatment
The subject has received any investigational agent within 28 days before the first dose of study treatment
Received any investigational agent within the 14 days before the start of study treatment (1st dose of ALT-803)
Patient has an infection requiring treatment with systemic antibiotics or antiviral medication or has completed treatment for such an infection within 14 days prior to planned first dose of study drug
Active infection requiring within 2 weeks prior to first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before enrollment; active infection requiring systemic therapy
Serious, systemic infection requiring treatment ? 7 days before the first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of study drug.
Serious, systemic infection requiring treatment =< 7 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before enrollment
Recent culture-documented infection requiring intravenous antimicrobials that was completed =< 7 days before the first dose of study drug or any uncontrolled active systemic infection; fever of unknown origin is not an exclusion criterion, as this may be disease-related
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Recent infection requiring systemic treatment that was completed
Patient has an active systemic infection requiring treatment or within 14 days before first dose of PRLX 93936.
Recent culture-documented infection requiring systemic intravenous treatment that was completed =< 7 days before the first dose of study drug or any uncontrolled active systemic infection; fever of unknown origin is not an exclusion criterion, as this may be disease-related
Active infection requiring treatment ? 7 days before first dose of study drug
Has an active infection or recent history (<30 days before study drug administration) requiring systemic treatment
Recent infection requiring systemic treatment that was completed =< 14 days before starting treatment on the study
Recent infection requiring systemic treatment that was completed =< 14 days before the first dose of study drug
Active infection requiring treatment ?7 days before the first dose of study drug
Recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drug
Active infection at initiation of study; recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drug
Evidence of active viral, bacterial, or systemic fungal infection requiring systemic treatment within 7 days prior to the first dose of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 7 days prior to the first dose of study drug.
Any uncontrolled active systemic infection or recent infection requiring intravenous anti-infective treatment that was completed =< 14 days before the first dose of study drug
Subject has evidence of an active infection requiring systemic therapy within 14 days prior to the planned first dose of study drug.
Subject has evidence of active infection requiring systemic therapy within 14 days prior to the first dose of study drug.
Recent infection requiring intravenous (IV) systemic treatment that was completed ?14 days before the first dose of study drug.
Patient with an infection requiring treatment with systemic antibiotics or antiviral medication or has completed treatment for such an infection within 4 days prior to planned initial dose of WT2725.
Serious infection within 14 days before the first dose of study drug. Participant must have recovered from infection before first dose.
Recent infection requiring IV anti-infective treatment that was completed ?14 days before the first dose of study drug
Recent infection requiring intravenous systemic treatment that was completed =< 14 days before the first dose of study drug or any uncontrolled active systemic infection
Recent infection requiring systemic treatment that was completed =< 7 days before the first dose of study drug
Active infection requiring within 2 weeks prior to first dose of study drug
No previous chemotherapy within 16 days prior to enrollment except for bleomycin which cannot have been given within 5 days prior to enrollment
Prior treatment with intracystic P-32 or intracystic bleomycin
Significant co-morbid respiratory disease that contraindicates the use of bleomycin
Prior treatment with bleomycin
Prior treatment with intracystic P-32, intracystic bleomycin or radiosurgery
Use of bleomycin (chemotherapy agent)
The patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug
Must use a condom if having sex with a pregnant woman
Men must agree to use adequate contraception; specifically, they must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; they must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
While receiving chemotherapy, the patient must use a condom if having sex with a pregnant woman
Must use a condom if having sex with a pregnant woman
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.
Must use a condom when having sex with a pregnant woman from the time of the first dose of study drug through 105 days after last dose of study drug. An additional highly effective form of contraception must be used from the time of the first dose of study drug through 105 days after last dose of study drug when having sex with a non pregnant female partner of childbearing potential.
All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of the study
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Female sex
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months following the last dose of study drug
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Men on study must use a condom if having sex with a pregnant woman
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential OR agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug; abstinence is an acceptable method of birth control
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Men must agree to use adequate contraception; specifically, they must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 120 days (4 months) following the last dose of study drug; they must also agree not to donate sperm during the study and for 4 months after receiving the last dose of study drug
Throughout the study, male subject must use a condom if having sex with a pregnant woman.
Male subject must use a condom, if having sex with a pregnant woman.
Throughout the study, patients must use a condom if having sex with a pregnant woman
Patients who are having sex that could lead to pregnancy must agree to contraceptive use during the entire study period
Condom (barrier method of contraception even if having sex with a pregnant woman)
Male patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of study drug through 105 days after last dose of study drug. Contraception should be considered for a nonpregnant female partner of childbearing potential.
Must use a condom if having sex with a pregnant woman
Must use a condom if having sex with a pregnant woman
Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.
Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.
Male patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of talazoparib through 105 days after the last dose. Contraception should be considered for a nonpregnant female partner of childbearing potential.
Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Administration of an investigational drug in the 28 days before the first dose of study treatment
Patients must not have received an investigational drug within 14 days
Participants may not be receiving treatment with any investigational drug or biologic within 30 days of randomization or at any time during the study.
Use of an investigational small molecule drug during the 30 days prior to screening or use of an investigational oligonucleotide or biologic drug during the prior 90 days
Patients who have received treatment with an investigational drug within 30 days preceding the first dose of study medication
The patient has received an investigational drug within 30 days of the first dose of study drug.
Treatment with any investigational drug 30 days prior to randomization
Patient has received an investigational drug within 14 days of enrollment
Any other investigational drug within 30 days prior to registration and during the study
Has received an investigational therapy within 30 days of first dose of study drug
Treatment with an investigational drug study within 28 days of before starting on study treatment
Treatment with any investigational drug within 30 days prior to registration.
Investigational drug use within 28 days of C1D1
Any investigational drug within 28 days prior to study treatment.
Use of any investigational drug within 14 days prior to the first dose of study drug
Patients who have been treated with an investigational agent within 21 days prior to the first dose of study drug.
The use of another investigational drug within the previous 30 days
Investigational therapy, defined as any drug that has not been approved for marketing for any indication in cGVHD will be restricted from the study
Treatment with a non-approved or investigational drug within 30 days prior to day 1 of study treatment
Patients who have received treatment with an investigational drug within 30 days preceding the first dose of study medication
Use of other investigational drug within 28 days of enrollment.
Treatment with a non-approved or investigational drug within 28 days of study treatment
Recipient must not have received any investigational drug within 30 days of starting conditioning treatment
Received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug
Patients receiving an investigational drug within 10 days prior to registration
Received any investigational compound within 28 days prior to the first dose of study drug or planned during the treatment period or follow-up
Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)
Treatment with a non-approved or investigational drug within 28 days of study treatment
Investigational agent received within 30 days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drug
Concurrent enrollment in any other study using an investigational drug
Patient may not be receiving any other investigational drug
Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
Treatment with an approved or investigational chemotherapy drug within 28 days of Day 1
Treatment with an approved or investigational anti-CD20 drug within 28 days of Day 1
Treatment with an approved or investigational biologic drug that does not target CD20 within 90 days of Day 1
Patient on other investigational drug
Treatment with an investigational therapeutic drug within 30 days of cycle 1
Patients participating in an investigational new drug protocol within 14 days before enrollment.
Prior therapy with TEW-7197 or received any investigational drug within the prior 28 days
Treatment with any investigational drug within 30 days prior to registration.
Use of any other investigational drug
Any anti-cancer treatment within 14 days or any investigational agent within 30 days before the first dose of study drug.
Use of any investigational drug within 14 days prior to the first dose of study drug
Treatment with any investigational drug within 28 days before randomisation.
Investigational drug within 30 days of first trilaciclib (G1T28) dose
Administration of any investigational agent within 28 days of first dose of study drug
Current or recent (within 30 days of first study dosing) treatment with another investigational drug or participation in another investigational study
Treatment with any investigational drug within 28 days prior to randomization
Another investigational drug
Patients participating in an investigational new drug protocol within 14 days before enrollment
Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment
Administration of any investigational agent within 28 days of first dose of study drug
Investigational drug use within 28 days of randomization.
Subjects who have received investigational agents within 28 days of the first day of study drug.
Patient who has participated in a prior therapeutic investigational drug study within 30 days prior to enrollment
Patients must not have prior treatment with any investigational drug within the preceding 28 days and must not be planning to receive any other investigational drug for the duration of the study
Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol; (subject must have recovered from all acute effects of previously administered investigational agents)
Use of any investigational drug (including marketed drugs not approved for this indication) within 14 days prior to the first dose of study drug
Other investigational treatment during or within 21 days before starting study treatment
Use of an investigational treatment from 30 days prior to the first dose of SNX-5422 and during the study.
History of receiving any investigational treatment within 21 days prior to enrollment into the study
Administration of any non-oncologic investigational drug within 28 days prior to receiving the first dose of therapy
Use of an investigational anti-cancer drug within 28 days preceding the first dose of dabrafenib
Treatment with any anti-cancer investigational drug within 28 days prior to commencing study treatment
Treatment with a non-approved or investigational drug within 30 days before visit 1
Receipt of another investigational drug within 14 days of enrollment.
Patients receiving other investigational medication (including investigational immunotherapy for NSCLC) or having received such medication within 30 days before entering the protocol
Patients may not be receiving any other investigational agents nor have received any investigational drug 30 days prior to enrollment
Use of an investigational drug within 30 days prior to screening.
Investigational agent received within 30 days prior to the first dose of study drug; if received any investigational agent prior to this time point, drug-related toxicities must have recovered to grade 2 or less prior to first dose of study drug
Chemotherapy or investigational drug therapy for cancer up to 21 days prior to day-1 of study.
Participation in any investigational drug study within 28 days prior to ISF35 administration; (subject must have recovered from all acute effects of previously administered investigational agents)
Treatment with a non-approved or investigational drug or agent within 30 days before day 1 of trial treatment
Treatment with an unapproved, investigational agent within 21 days of the first dose of study drug
Treatment with any investigational anticancer drug within 21 days of the first study\n             treatment administration
investigational drug within 28 days
investigational drug within the 28 days prior to planned first dose of study drug, or
Patients who have received any investigational drug within 28 days prior to Day 1 of study entry (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Treatment with a non-approved or investigational drug within 30 days prior to day 1 of study treatment
Treatment with an unapproved, investigational therapeutic agent, immunotherapy or biological therapy within 21 days prior to the first dose of study drug
Receipt of an investigational drug within 28 days prior to initiation of study treatment
Receipt of an investigational drug within 28 days prior to study start
Investigational drug use within 28 days of the first dose of PLX3397
Treatment with a investigational drug within 28 days before Day 1 of trial treatment.
Treatment within the last 30 days with any investigational drug
Use of an investigational therapeutic within 30 days
Patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study
Subjects who are receiving any other investigational agents or have received another investigational drug in the last 30 days
Enrollment in another investigational drug trial
Patients who have received any investigational medication within 6 weeks of enrollment, or who are scheduled to receive an investigational drug during the course of the study
Patient receiving any investigational drug for hyperuricemia within 30 days of planned first treatment with rasburicase
Any investigational drug being administered during the study
Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study
Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study
Patient aged < 6 years who received any investigational drug (defined as a medication with no marketing authorization granted for any age class and any indication) within 90 days prior to Day 1, or patient aged 6 years who received any investigational drug within 30 days prior to Day 1 or is expected to receive investigational drugs prior to study completion.
Patients who have received an investigational drug within 30 days of enrollment in study
Has participated in any Phase 1 Investigational New Drug (IND) study within prior 30 days or expects to do so within the following 60 days
Have received any investigational new drug within the past 30 days or planning to receive such during the study period
Administration of chemotherapy or any investigational drug in the 28 days prior to receiving the first dose of treatment.
Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours (h) afterwards
Treatment with another investigational drug or other intervention with 24 hours of injection
Received an investigational drug within 30 days prior to first dose of panitumumab IRDye800
Received an investigational drug within 30 days prior to first dose of cetuximab IRDye800
Patient must not be receiving an investigational drug
Received an investigational drug within 30 days prior to first dose of cetuximab-IRDye800
Treatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug; subjects must have recovered from AEs due to previously administered therapies.
Received investigational therapy with another drug or biologic within 30 days prior to the start of CMP-001 dosing on W1D1. However, if an investigational drug has a short half-life, a shorter wash out period may be acceptable upon permission given by the Sponsor.
Investigational drug use within 28 days of the first dose of avelumab
Received an investigational drug within 30 days prior to first dose of cetuximab IRDye800
Administration of any investigational therapeutic within 30 days of enrollment
Have taken an investigational drug within 30 days of enrollment.
The patient has received an investigational drug within 30 days of the first dose of study drug.
Subjects who have taken an investigational drug within 30 days of enrollment.
Subjects who have taken an investigational drug within 30 days of enrollment.
Use of an investigational drug within 21 days prior to the first dose of study drug. Note that to be eligible, any drug-related toxicity should have recovered to Grade 1 or less, with the exception of alopecia.
